May. 19 at 10:36 AM
Truist assumed coverage on
$RAPP and said: We are assuming coverage of RAPP with the firm's prior BUY rating and are raising our price target to
$56 (from
$44).
$PRAX MPLT ALKS BHVN JAZZ VNDA UCBJY
$XENE
Truist added—Our thesis is largely consistent with the firm's most recent published view: we see RAP-219 as an attractive, differentiated epilepsy asset, with early efficacy data suggestive of best-in-category potential in focal onset seizures (FOS). We also see upside optionality in bipolar mania, which is not reflected in our current projections.
